Cellectis S.A. ADR (CLLS)
NASDAQ: CLLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $92.76M
- EPS (TTM)
- -$1.26
- Dividend yield
- None
- 52-week range
- 0.881 – 5.45
- Day range
- 0.9028 – 0.9957
- Volume / Avg
- 52.63K / 115.00K
- Beta
- —
- Shares outstanding
- 72.73M
52-week range
CLLS stock today
Cellectis S.A. (CLLS) closed at $0.9209 on Nov 20, down 7.89% (-$0.0789), versus the S&P 500's 3.70% decline. Trading was light, with 52.63K shares changing hands, about 46% of the average daily volume. At this level, CLLS sits near the bottom of its 52-week range of $0.881 to $5.45: 83.1% below the high, set on Dec 11, 2025 and 4.5% above the low.
CLLS is down 81.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.4%. Cellectis S.A. has posted a net loss over the last twelve months (EPS of -$1.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cellectis S.A.
Company profileCellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Andre Choulika Ph.D.
- Headquarters
- Paris
- Employees
- 224
- IPO year
- 2015
- Website
- cellectis.com
Financial highlights
Full financialsIn fiscal 2025, Cellectis S.A. generated $72.9 million in revenue, up 75.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Cellectis S.A. reported a net loss of $67.6 million, compared with a loss of $36.8 million a year earlier. Gross margin was 100.0% (flat year over year) and operating margin -45.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $72.95M | $41.51M | $755.00K | $19.17M | $30.35M |
| Growth | +75.76% | +5397.35% | -96.06% | -36.83% | -40.56% |
| Net income | $-67.59M | $-36.76M | $-101.06M | $-106.14M | $-114.20M |
| EPS (diluted) | $-0.67 | $-0.41 | $-1.77 | $-2.33 | $-2.55 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$5.50+497.24%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.01 vs —
CLLS news
All CLLS news- Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswire
- Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activitésGlobeNewswire
- Cellectis to Report Third Quarter Financial Results on November 12, 2026GlobeNewswire
- Cellectis publiera ses résultats financiers du troisième trimestre le 12 novembre 2026GlobeNewswire
- Monthly information on share capital and company voting rightsGlobeNewswire
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialGlobeNewswire
- Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026Nasdaq
- Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026GlobeNewswire
Cellectis S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs CLLS |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs CLLS |
| NTHINeOnc Technologies Holdings Inc. | 3.15 | -9.48% | $90.88M | vs CLLS |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs CLLS |
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs CLLS |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs CLLS |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs CLLS |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs CLLS |
Indexes, lists and sector
Cellectis S.A. stock FAQ
What is Cellectis S.A.'s stock price today?
CLLS last traded at $0.9209 as of Nov 20, 4:00 PM EST, down 7.89% on the day. Prices are delayed at least 15 minutes.
Who is Cellectis S.A.'s CEO?
Dr. Andre Choulika Ph.D. is the chief executive officer of Cellectis S.A. ADR, which has about 224 employees.
What is the CLLS 52-week high?
The 52-week high for CLLS is $5.45 and the 52-week low is $0.881. The stock is currently 83.1% below its high.